End-of-day quote
Shanghai S.E.
23:00:00 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
30.63
CNY
|
+5.44%
|
|
+7.10%
|
+26.67%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,785
|
7,539
|
8,681
|
12,397
|
9,742
|
10,423
|
Enterprise Value (EV)
1 |
4,337
|
5,693
|
6,490
|
9,901
|
7,073
|
7,644
|
P/E ratio
|
32.7
x
|
20.8
x
|
20.8
x
|
26.6
x
|
20.4
x
|
23.5
x
|
Yield
|
1.12%
|
1.49%
|
1.49%
|
1.22%
|
1.55%
|
1.65%
|
Capitalization / Revenue
|
2.63
x
|
2.79
x
|
3.11
x
|
3.66
x
|
2.76
x
|
3.32
x
|
EV / Revenue
|
1.97
x
|
2.1
x
|
2.32
x
|
2.92
x
|
2
x
|
2.44
x
|
EV / EBITDA
|
12.8
x
|
14.2
x
|
17
x
|
20.1
x
|
13.2
x
|
17.9
x
|
EV / FCF
|
21.1
x
|
17
x
|
10.5
x
|
35.2
x
|
26.9
x
|
58.9
x
|
FCF Yield
|
4.75%
|
5.88%
|
9.48%
|
2.84%
|
3.72%
|
1.7%
|
Price to Book
|
2.55
x
|
2.95
x
|
3.05
x
|
3.91
x
|
2.79
x
|
2.79
x
|
Nbr of stocks (in thousands)
|
431,054
|
431,054
|
431,054
|
431,054
|
431,054
|
431,054
|
Reference price
2 |
13.42
|
17.49
|
20.14
|
28.76
|
22.60
|
24.18
|
Announcement Date
|
27/04/19
|
24/04/20
|
25/03/21
|
22/03/22
|
07/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,198
|
2,705
|
2,792
|
3,385
|
3,532
|
3,137
|
EBITDA
1 |
340.1
|
402.3
|
381.9
|
491.5
|
535.1
|
427.1
|
EBIT
1 |
306.2
|
368.7
|
349.1
|
453.4
|
494.3
|
384.7
|
Operating Margin
|
13.93%
|
13.63%
|
12.5%
|
13.39%
|
13.99%
|
12.27%
|
Earnings before Tax (EBT)
1 |
191.7
|
422.4
|
497.7
|
548.2
|
559.1
|
524.7
|
Net income
1 |
176.2
|
360
|
419.1
|
464.6
|
479
|
443.3
|
Net margin
|
8.02%
|
13.31%
|
15.01%
|
13.72%
|
13.56%
|
14.13%
|
EPS
2 |
0.4100
|
0.8400
|
0.9700
|
1.080
|
1.110
|
1.030
|
Free Cash Flow
1 |
205.8
|
334.9
|
615.5
|
281.2
|
263.4
|
129.8
|
FCF margin
|
9.37%
|
12.38%
|
22.05%
|
8.31%
|
7.46%
|
4.14%
|
FCF Conversion (EBITDA)
|
60.52%
|
83.24%
|
161.14%
|
57.22%
|
49.21%
|
30.39%
|
FCF Conversion (Net income)
|
116.81%
|
93.03%
|
146.87%
|
60.54%
|
54.98%
|
29.28%
|
Dividend per Share
2 |
0.1500
|
0.2600
|
0.3000
|
0.3500
|
0.3500
|
0.4000
|
Announcement Date
|
27/04/19
|
24/04/20
|
25/03/21
|
22/03/22
|
07/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,448
|
1,846
|
2,192
|
2,496
|
2,669
|
2,779
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
206
|
335
|
615
|
281
|
263
|
130
|
ROE (net income / shareholders' equity)
|
7.12%
|
14.2%
|
15.4%
|
15.1%
|
13.9%
|
12.1%
|
ROA (Net income/ Total Assets)
|
6.74%
|
7.42%
|
6.1%
|
7.09%
|
6.73%
|
4.85%
|
Assets
1 |
2,615
|
4,852
|
6,868
|
6,553
|
7,121
|
9,141
|
Book Value Per Share
2 |
5.270
|
5.930
|
6.610
|
7.360
|
8.110
|
8.670
|
Cash Flow per Share
2 |
2.570
|
3.570
|
4.810
|
5.640
|
5.780
|
6.930
|
Capex
1 |
25
|
46.4
|
45.4
|
65.1
|
75
|
248
|
Capex / Sales
|
1.14%
|
1.71%
|
1.63%
|
1.92%
|
2.12%
|
7.92%
|
Announcement Date
|
27/04/19
|
24/04/20
|
25/03/21
|
22/03/22
|
07/04/23
|
12/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +26.67% | 1.73B | | +22.69% | 43.81B | | +25.56% | 23.01B | | +18.00% | 15.27B | | +8.91% | 13.68B | | +42.72% | 11.96B | | -7.49% | 6.98B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.26% | 5.59B |
Generic Pharmaceuticals
|